Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease.

Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, Schreiber NT, Johnson SC, Atwood CS, Puglielli L, Hermann BP, McBride PE, Stein JH, Sager MA, Asthana S.

J Alzheimers Dis. 2008 Mar;13(2):187-97.

PMID:
18376061
2.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
3.

Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease.

Höglund K, Syversen S, Lewczuk P, Wallin A, Wiltfang J, Blennow K.

Exp Brain Res. 2005 Jul;164(2):205-14. Epub 2005 Jun 4.

PMID:
15937702
4.

Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.

Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER.

J Alzheimers Dis. 2006 Dec;10(4):399-406.

PMID:
17183151
5.

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial.

Simons M, Schwärzler F, Lütjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB.

Ann Neurol. 2002 Sep;52(3):346-50.

PMID:
12205648
6.

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1080-6. doi: 10.1136/jnnp.2009.199950. Epub 2010 Jun 14.

PMID:
20547614
7.

The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.

Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A, Vanmechelen E, Vanderstichele H, Lutjohann D, Blennow K.

Dement Geriatr Cogn Disord. 2005;19(5-6):256-65. Epub 2005 Mar 21.

PMID:
15785028
8.

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.

Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS.

Neurology. 2011 Aug 9;77(6):556-63. doi: 10.1212/WNL.0b013e318228bf11. Epub 2011 Jul 27.

9.

Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.

Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H.

J Alzheimers Dis. 2012;29(1):171-6. doi: 10.3233/JAD-2012-111361.

PMID:
22214781
10.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
11.

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5856-61. Epub 2001 Apr 10.

12.

Statins for the treatment of dementia.

McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007514. doi: 10.1002/14651858.CD007514.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;7:CD007514.

PMID:
20687089
13.

Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.

Paternicò D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, Baronio M, Amicucci G, Frisoni GB.

Alzheimers Dement. 2012 Nov;8(6):520-7. doi: 10.1016/j.jalz.2011.10.003. Epub 2012 Jun 6.

PMID:
22677492
14.

Selective benefits of simvastatin in bitransgenic APPSwe,Ind/TGF-β1 mice.

Papadopoulos P, Tong XK, Hamel E.

Neurobiol Aging. 2014 Jan;35(1):203-12. doi: 10.1016/j.neurobiolaging.2013.07.010. Epub 2013 Aug 15.

PMID:
23954171
15.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
16.

Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.

Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J.

J Alzheimers Dis. 2011;24(3):537-46. doi: 10.3233/JAD-2011-101878.

PMID:
21297262
17.

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group..

Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Erratum in: Lancet Neurol. 2009 Nov;8(11):981.

PMID:
18672400
18.

Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.

Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, Zhang J, Lampe J, Craft S.

JAMA Neurol. 2013 Aug;70(8):972-80. doi: 10.1001/jamaneurol.2013.396.

19.

Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.

Lasser RA, Dukoff R, Levy J, Levin R, Lehtimäki T, Seubert P, Sunderland T.

Int J Geriatr Psychiatry. 1998 Nov;13(11):767-74.

PMID:
9850873
20.

Statins of different brain penetrability differentially affect CSF PLTP activity.

Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WR, Albers JJ.

Dement Geriatr Cogn Disord. 2006;22(5-6):392-8. Epub 2006 Sep 7.

PMID:
16960448

Supplemental Content

Support Center